Literature DB >> 18431543

Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma.

Marc Diensthuber1, Marc Potinius, Thomas Rodt, Alexandru C Stan, Hans-J Welkoborsky, Madjid Samii, Jonas Schreyögg, Thomas Lenarz, Timo Stöver.   

Abstract

Erythropoietin (Epo) expression is regulated via hypoxia-inducible factor (HIF)-1alpha-directed gene transcription. Activation of the erythropoietin receptor (EpoR) by Epo leads to elevated expression of the anti-apoptotic protein, bcl-2, which has recently been shown to promote angiogenesis in malignant tumors. Expression of HIF-1alpha, Epo, EpoR, and bcl-2 was studied by immunohistochemistry in a series of 20 olfactory neuroblastoma (ONB) samples. Data were correlated with microvessel density, proliferative activity, and apoptosis in the specimens and survival analysis was performed to investigate the prognostic value of the examined factors. Immunohistochemical analysis revealed robust expression of HIF-1alpha, Epo, EpoR, and bcl-2 in ONB. Ninety percent of the samples showed HIF-1alpha immunoreactivity and in 60% of the cases, bcl-2 immunoreactivity was observed. A significant positive correlation between the expression levels of HIF-1alpha and bcl-2 and the microvessel density was found. Survival analysis did not reveal any prognostic significance for the tested factors. Expression of HIF-1alpha, Epo, Epo-R, and bcl-2 may play a functional role in ONB pathogenesis. Our data suggest that bcl-2 may act as a stimulator of angiogenesis in ONB, and thus represents a novel target for anti-angiogenic treatment strategies in the therapy of ONB.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18431543     DOI: 10.1007/s11060-008-9602-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

Review 1.  Angiogenesis in neuroblastoma.

Authors:  Domenico Ribatti; Danilo Marimpietri; Fabio Pastorino; Chiara Brignole; Beatrice Nico; Angelo Vacca; Mirco Ponzoni
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

2.  Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.

Authors:  R Bos; H Zhong; C F Hanrahan; E C Mommers; G L Semenza; H M Pinedo; M D Abeloff; J W Simons; P J van Diest; E van der Wall
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

3.  Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity.

Authors:  Angela Iervolino; Daniela Trisciuoglio; Domenico Ribatti; Antonio Candiloro; Annamaria Biroccio; Gabriella Zupi; Donatella Del Bufalo
Journal:  FASEB J       Date:  2002-07-01       Impact factor: 5.191

4.  Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.

Authors:  Geza Acs; Paul J Zhang; Cindy M McGrath; Peter Acs; John McBroom; Ahmed Mohyeldin; Suzhen Liu; Huasheng Lu; Ajay Verma
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

5.  Co-expression of transforming growth factor-beta1 and glial cell line-derived neurotrophic factor in vestibular schwannoma.

Authors:  M Diensthuber; A Brandis; T Lenarz; T Stöver
Journal:  Otol Neurotol       Date:  2004-05       Impact factor: 2.311

Review 6.  Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors.

Authors:  N Weidner
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

7.  Topographical dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissues.

Authors:  C M Chleq-Deschamps; D P LeBrun; P Huie; D P Besnier; R A Warnke; R K Sibley; M L Cleary
Journal:  Blood       Date:  1993-01-15       Impact factor: 22.113

8.  Expression of erythropoietin by the human placenta.

Authors:  K P Conrad; D F Benyo; A Westerhausen-Larsen; T M Miles
Journal:  FASEB J       Date:  1996-05       Impact factor: 5.191

9.  Olfactory neuroblastoma. An immunohistochemical, ultrastructural, and flow cytometric study.

Authors:  T Hirose; B W Scheithauer; M B Lopes; H A Gerber; H J Altermatt; S G Harner; S R VandenBerg
Journal:  Cancer       Date:  1995-07-01       Impact factor: 6.860

Review 10.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

View more
  8 in total

Review 1.  Prognosis and biology in esthesioneuroblastoma: the emerging role of Hyams grading system.

Authors:  Rami E Saade; Ehab Y Hanna; Diana Bell
Journal:  Curr Oncol Rep       Date:  2015-01       Impact factor: 5.075

2.  Hypoxia inducible factor-1α/B-cell lymphoma 2 signaling impacts radiosensitivity of H1299 non-small cell lung cancer cells in a normoxic environment.

Authors:  Gang Wang; Liang Xiao; Fen Wang; Jing Yang; Li Yang; Ye Zhao; Wensen Jin
Journal:  Radiat Environ Biophys       Date:  2019-06-15       Impact factor: 1.925

3.  Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells.

Authors:  D Trisciuoglio; C Gabellini; M Desideri; Y Ragazzoni; T De Luca; E Ziparo; D Del Bufalo
Journal:  Cell Death Differ       Date:  2011-01-14       Impact factor: 15.828

4.  Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90.

Authors:  Daniela Trisciuoglio; Chiara Gabellini; Marianna Desideri; Elio Ziparo; Gabriella Zupi; Donatella Del Bufalo
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

5.  Changing Trends in the Management of Esthesioneuroblastoma: Irish and International Perspectives.

Authors:  Robbie S R Woods; Thavakumar Subramaniam; Mary Leader; Rory McConn-Walsh; James Paul O'Neill; Peter D Lacy
Journal:  J Neurol Surg B Skull Base       Date:  2017-11-01

Review 6.  Erythropoietin and Its Angiogenic Activity.

Authors:  Patrícia Kimáková; Peter Solár; Zuzana Solárová; Radovan Komel; Nataša Debeljak
Journal:  Int J Mol Sci       Date:  2017-07-13       Impact factor: 5.923

7.  Dramatic response to targeted therapy in an aggressive olfactory neuroblastoma: illustrative case.

Authors:  Saksham Gupta; Wenya Linda Bi; Donald J Annino; Ian F Dunn
Journal:  J Neurosurg Case Lessons       Date:  2022-06-13

Review 8.  Genetic and molecular alterations in olfactory neuroblastoma: implications for pathogenesis, prognosis and treatment.

Authors:  Piotr Czapiewski; Michał Kunc; Johannes Haybaeck
Journal:  Oncotarget       Date:  2016-08-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.